Pharmacokinetics and clinical effectiveness of methylphenidate

Clinical Pharmacokinetics

Volumn 37, Issue 6, 1999, Pages 457-470

  Kimko, Hui C ^a   Cross, James T ^a   Abernethy, Darrell R ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ATTENTION DEFICIT DISORDER; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; HUMAN; LONG TERM CARE; PHARMACODYNAMICS; PRIORITY JOURNAL; RACEMIC MIXTURE; REVIEW;

EID: 0033373766     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937060-00002     Document Type: Review

References (75)

1. 3H]-dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. J Pharmacol Exp Ther 1979; 210: 422-8
2. 2. Patrick KS, Caldwee RW, Ferris RM, et al. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 1987; 241 (1); 152-8
3. 3. Volkow N, Wang G, Fowler J, et al. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 1999; 156 (1): 19-26
4. 4. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94: 127-52
5. 5. Safer DJ, Krager JM. A survey of medication treatment for hyperactive/inattentive students. JAMA 1988; 260: 2256-8
6. 6. Glock MH, Jensen PS, Cooper JR, editors. Diagnosis and treatment of attention deficit hyperactivity disorder [bibliography online]. Bethesda (MD): National Library of Medicine, 1998: http://www.nlm.nih.gov/pubs/cbm/adhd.html [accessed 1999 Nov 10]
7. 14C: studies in man and animals. J Pharmacol Exp Ther 1974; 191 (3): 535-47
8. 8. Gualtieri CT, Wargin W, Kanoy R, et al. Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry 1982; 21 (1): 19-26
9. 9. Milberg RM, Rinehart Jr KL, Sprague RL, et al. A reproducible gas chromatographic mass spectrometric assay for low levels of methylphenidate and ritalinic acid in blood and urine. Biomed Mass Spectrometry 1975; 2: 2-8
10. 10. Srinivas NR, Hubbard JW, Korchinski ED, et al. Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm Res 1993; 10 (1): 14-21
11. 11. Srinivas NR, Hubbard JW. Quinn D, et al. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 1992; 52: 561-8
12. 12. Shaywitz SE, Hunt RD, Jatlow P, et al. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 1982; 69 (6): 688-94
13. 13. Physicians' desk reference. 50th ed. Montvale (NJ): Medical Economics, 1996
14. 14. Yoss RE, Daly DD. On the treatment of narcolepsy. Med Clin North Am 1968; 69: 161-3
15. 15. Oettinger Jr L, Majovski LV. 1976. Methylphenidate: a review. South Med J 1976; 69 (2): 161-3
16. 16. Gualtieri CT, Wargin W, Kannoy R, et al. The effects of eating and fasting on the absorption of methylphenidate. Res Commun Psychol Psychiatry Behav 1982; 7: 381-4
17. 17. Chan YM, Swanson JM, Soldin SJ, et al. Methylphenidale hydrochloride given with of before breakfast; II. Effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics 1983; 72 (1): 56-9
18. 18. Swanson JM, Sandman CA, Deutsch C, et al. Methylphenidate hydrochloride given with or before breakfast: I. Behavioral, cognitive, and electrophysiologic effects. Pediatrics 1983; 72: 49-55
19. 11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. Synapse 1994; 18: 152-60
20. 20. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Arch Gen Psychiatry 1995, 52: 456-63
21. 21. Hungund BL, Perel JM, Hurwic MJ, et al. Pharmacokinetics of methylphenidate in hyperkinetic children. J Clin Pharmacol 1979; 8: 571-6
22. 22. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocrin Rev 1989; 10: 232-74
23. 23. Srinivas NR, Quinn D, Hubbard JW, et al. Stereoselective disposition of methylphenidate in children with attention-deficit disorder. J Pharmacol Exp Ther 1987; 241: 300-6
24. 24. Hubbard JW, Srinivas NR, Quinn D, et al. Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. J Pharm Sci 1989; 78 (11): 944-7
25. 25. Srinivas NR, Hubbard JW, Midha KK. Enantioselective gas chromatographic assay with electron-capture detection for dl-ritalinic acid in plasma. J Chromatogr 1990; 530: 327-36
26. 26. Aoyama T, Kotaki H, Honda Y, et al. Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method. J Pharm Sci 1990; 79 (6): 465-9
27. 27. Wargin W, Patrick KS, Gualtieri CT, et al. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 1983; 226 (2): 382-6
28. 28. Egger H, Bartlett F, Dreyfuss R, et al. Metabolism of methylphenidate in dog and rat. Drug Metab Disp 1981; 9 (5): 415-23
29. 29. Birmaher B, Greenhill LL, Cooper TB, et al. Sustained release methylphenidate: pharmacokinetic studies in ADHD males. J Am Acad Child Adolesc Psychiatry 1989; 28 (5): 768-72
30. 30. Pelham WE, Sturges J, Hoza J, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pcdialrics 1987; 80 (4): 491-501
31. 31. Srinivas NR, Hubbard Jw, Korchinski ED, et al. Stereoselective urinary pharmacokinetics of dl-threo-methylphenidate and its major metabolite in humans. J Pharm Sci 1992; 81 (8): 747-9
32. 32. Aoyama T, Kotaki H, Sasaki T, et al. Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. Eur J Clin Pharmacol 1993; 44: 79-84
33. 33. Aoyama T, Kotaki H, Iga T. Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats. J Pharmacobio-Dynam 1990; 13: 647-52
34. 34. Patrick KS, Straughn AB, Jarvi EJ, et al. The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. Biopharm Drug Disp 1989; 10: 165-71
35. 35. Rapport MD, DuPaul GJ, Kelly KL. Attention deficit hyperactivity disorder and methylphenidate: the relationship between gross body weight and drug response in children. Psychopharmacol Bull 1989; 25 (2): 285-90
36. 36. Rapport MD, Denney MA. Titrating methylphenidate in children with attention-deficit/hyperactivity disorder: is body mass predictive of clinical response? J Am Acad Child Adolesc Psychiatry 1997; 36 (4): 523-30
37. 37. Gualtieri CT, Hicks RE, Patrick K, et al. Clinical correlates of methylphenidate blood levels. Ther Drug Monit 1984; 6 (4): 379-92
38. 38. Janowsky DS, Leichner P, Clopton P, et al. Comparison of oral and intravenous methylphenidate. Psychopharmacology 1978; 59: 75-8
39. 39. Aoyama R, Kotaki H, Sawada Y, et al. Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats. Psychopharmacology 1996; 127: 117-22
40. 40. Patrick KS, Ellington KR, Breese GR. Distribution of methylphenidate and p-hydroxymethylphenidate in rats. J Pharmacol Exp Ther 1984; 231 (1): 61-5
41. 41. Swanson J, Kinsbourne M, Roberts W, et al. Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 1978; 61 (1): 21-9
42. 42. Stoner G, Carey SP, Ikeda MJ, et al. The utility of curriculum-based measurement for evaluating the effects of methylphenidate on academic performance. J App Behav Anal 1994; 27: 101-13
43. 43. Taylor E, Schachar R, Thorley HM, et al. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 1987; 17: 121-43
44. 44. Buitelaar JK, Rutger JVG, Swaab-Barneveld H, et al. Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34 (8): 1025-32
45. 45. Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science 1977; 198: 1274-6
46. 46. Kupietz SS, Winsberg BG, Richardson E, et al. Effects of methylphenidate dosage in hyperactive reading-disabled children: I. Behavior and cognitive performance effects. J Am Acad Child Adolesc Psychiatry 1988; 22: 70-7
47. 47. Rapport MD, DuPaul GJ, Stoner G, et al. Comparing classroom and clinic measures of attention deficit disorder: differential, idiosyncratic, and dose-response effects of methylphenidate. J Consult Clin Psychol 1986; 54: 334-41
48. 48. Rapport MD, Stoner G, DuPaul GH, et al Methylphenidate in hyperactive children: differential effects of dose on academic, learning, and social behavior. J Abnorm Child Psychol 1985; 13: 227-44
49. 49. Logan GD, Burkell J. Dependence and independence in responding to double stimulation: a comparison of stop, change and dual-task paradigms. J Exp Psychol Human Percept Perform 1986; 10: 549-63
50. 50. Tannock R, Schachar R, Logan G. Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. J Abnorm Child Psychol 1995; 23 (2): 235-66
51. 51. Solanto MV. Neuropharmacological basis of stimulant drug action in attention deficit disorder with hyperactivity. Psychol Bull 1984; 95: 387-409
52. 52. Solanto MV, Wender EH. Does methylphenidate constrict cognitive functioning? J Am Acad Child Adolesc Psychiatry 1989, 28: 897-902
53. 53. Tannock R, Schachar RJ, Carr RP, et al. Dose-response effects of methylphenidate on academic performance and overt behavior in hyperactive children. Pediatrics 1989; 84 (4): 648-57
54. 54. Tannock R, Schachar R. Methylphenidate and cognitive perseveration in hyperactive children. J Child Psychol Psychiatry 1992; 33 (7): 1217-28
55. 55. Rapport MD, Kelly KL. Psychostimulant effects on learning and cognitive function: findings and implications for children with attention deficit hyperactivity disorder. Clin Psychol Rev 1991; 11: 61-92
56. 56. Rapport MD, Denney MA, DuPaul GJ, et al. Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry 1994; 33 (6): 882-93
57. 57. Borcherding BG, Keysor BG, Cooper TB, et al. Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology 1989; 2: 255-63
58. 58. Rapport MD, Stoner G, DuPaul GJ, et al. Attention deficit disorder and methylphenidate: a multilevel analysis of dose-response effects on children's impulsivity across settings. J Am Acad Child Adolesc Psychiatry 1988; 27: 60-9
59. 59. Tannock R, Schachar RJ, Carr RP, et al. Effects of methylphenidate on inhibitory control in hyperactive children. J Abnorm Child Psychol 1989; 17: 473-91
60. 60. Abikoff H, Gittelman R. The normalizing effect of methylphenidate on the classroom behavior of ADHD children. J Abnorm Child Psychol 1985; 13: 33-44
61. 61. Klein R. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54: 1073-80
62. 62. Barkley RA, Cunningham E. The effect of methylphenidate on the mother-child interactions of hyperactive children. Arch Gen Pscyhiatry 1979; 36: 201-8
63. 63. Barkley RA, Karlsson J, Strzelecki E, et al. Effects of age and ritalin dosage on mother-child interactions of hyperactive children. J Consult Clin Psychol 1984; 52: 750-8
64. 64. Schachar R, Taylor E, Wieselberg M, et al. Changes in family function and relationships in children who respond to methylphenidate. J Am Acad Child Adolesc Psychiatry 1987; 26: 728-32
65. 65. Whalen CK, Henker B, Dotemoto S, et al. Hyperactivity and methylphenidate: peer interaction styles. In: Gasow KD, Loney J, editors. Psychosocial aspects of drug treatment for hyperactivity. Boulder (CO): Westview Press, 1981
66. 66. Whalen CK, Henker B, Granger DA. Social judgment processes in hyperactive boys: effects of methylphenidate and comparisons with normal peers. J Abnorm Child Psychol 1990; 18: 297-316
67. 67. Weiss G, Kruger E, Danielson R, et al. Effect of long term treatment of hyperactive children with methylphenidate. Can Med Assoc J 1975; 112: 159-65
68. 68. Hechtman LT, Weiss G, Perlman T. Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Adolesc Psychiatry 1984; 23 (3): 261-9
69. 69. Charles L, Schain R. A four-year follow-up study of the effects of methylphenidate on the behavior and academic achievement of hyperactive children. J Abnorm Child Psychol 1981; 9 (4): 495-505
70. 70. Arnold L. National Institute of Mental Health Collaborative Multimodal Treatment Study of children with ADHD (the MTA). Arch Gen Psychiatry 1997; 54 (8): 65-70
71. 71. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990; 86: 184-92
72. 72. Kelly KL, Rapport MD, DuPaul GJ. Attention deficit disorder and methylphenidate: a multi-step analysis of dose-response effects on children's cardiovascular functioning. Int Clin Psychopharmacol 1988; 3: 167-81
73. 73. Golden G. The effect of central nervous system stimulants on Tourette's syndrome. Ann Neurol 1977; 2: 69-70
74. 74. Law SF, Schachar MD. Do typical clinical doses of methylphenidate cause ties in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1999; 38 (8): 944-51
75. 75. Markowitz JS, Morrison SD, DeVane CL. Drug interactions with psychostimulants. Int Clin Psychohpharmacol 1999; 14: 1-18